Compare Pfizer Inc (PFE) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.56B), while Vanguard Total World Stock Index Fund ETF trades at $159.3 (market cap $101.70B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| PFE | VT | |
|---|---|---|
Market Cap | $158.56B | $101.70B |
Volume | 44,138,282 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $162.39 |
52-Week Low | $23.67 | $134.19 |
Typical Hold Time | 158 Days | 53 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
VT, the Vanguard Total World Stock ETF, trades at $159.39, down 0.16% on the day. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The ETF offers broad global diversification with over 9,700 stocks and a low expense ratio of 0.06%, though key valuation ratios like P/E and P/B are not disclosed in the provided data. Recent news highlights its role as a core holding for long-term investors seeking worldwide exposure.
The outlook for VT is supported by its cost efficiency and diversification benefits, but near-term technical weakness and competitive pressures from lower-fee alternatives pose risks. Investor sentiment is mixed, with some analysts favoring VT for its comprehensive coverage, while others point to higher expenses relative to peers. Macroeconomic uncertainties and trade tensions could impact global equity returns, affecting VT's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
